10-Q · July 15, 2026
CDT Equity Inc. reported a diluted EPS of $45,647.11 for Q1 2026, a remarkable turnaround from prior losses, although revenue remains undisclosed. Operating expenses remained stable with a slight decrease in R&D costs…
Earnings analysis · 10-Q
CDT earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, segment results, or quantitative guidance, so revenue, margins, EPS, cash flow, and working-capital trends cannot be…
Read full summary
The supplied 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, segment results, or quantitative guidance, so revenue, margins, EPS, cash flow, and working-capital trends cannot be assessed from the filing text provided. The principal disclosed negative is that disclosure controls remained ineffective as of June 30, 2026 because previously identified material weaknesses were not remediated. Litigation also remains material, including an approximately $7 million judgment against CPL that Strand is seeking to recover from CDT.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
No unreported equity sales or repurchases
The company reported no unregistered equity sales during the quarter ended June 30, 2026 and no common-stock repurchases during the six months ended June 30, 2026.
-
Management sees limited routine litigation impact
Management stated it does not expect pending ordinary-course claims to materially affect results, financial position, or cash flows, although the company disclosed a December 16, 2025 judgment against CPL of approximately $7 million plus interest and a portion of costs.
What to watch
-
Material weaknesses remain unresolved
Disclosure controls and procedures were concluded to be ineffective as of the fiscal quarter ended June 30, 2026, because previously identified material weaknesses had not been remediated.
-
Potential $7 million litigation exposure
Strand is seeking recovery from CDT of a December 16, 2025 High Court judgment against CPL for approximately $7 million, plus interest and a fraction of Strand’s costs; CDT denies liability.
-
Patent ownership dispute remains pending
The company disclosed a patent-entitlement proceeding initiated by St George Street Capital on December 18, 2024 concerning patent application PCT/IB2022/00775. The company disputes the claims and states that further updates will follow UK IPO notification.
Management's outlook
No quantitative revenue or EPS outlook is provided in the supplied 10-Q text. The filing does not provide operating forecasts or explicit guidance.
Earlier filings 4
10-K · April 15, 2026
CDT Equity (CDT) has repositioned as a lean, AI- and solid-form-driven drug-repositioning platform after licensing AZD1656, AZD5658 and AZD5904 from AstraZeneca and building related partnerships (Sarborg and Manoira).…
10-Q · August 14, 2025
CDT Equity (formerly Conduit Pharmaceuticals) reported a Q2 net loss of $6,028 (three months) and GAAP EPS of $(5.46), driven by a ramp in R&D and continued G&A. Liquidity improved materially — cash rose to $3,332 from…
10-Q · May 15, 2025
For the quarter ended March 31, 2025 Conduit Pharmaceuticals reported a net loss of $(5,146) (three months ended March 31, 2025) versus $(3,552) in the prior-year quarter, with basic and diluted net loss per share of…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.